Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06846398 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 in Adult Subjects With Hereditary Angioedema
A Phase 2 study of Hereditary Angioedema (HAE), sponsored by Shanghai Argo Biopharmaceutical Co..
- Active
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 18
- Study locations
NCT06846398: Active Phase 2 study of Hereditary Angioedema (HAE), sponsored by Shanghai Argo Biopharmaceutical Co..
NCT06846398 is a Phase 2 study of Hereditary Angioedema (HAE) that is active but no longer recruiting, run by Shanghai Argo Biopharmaceutical Co.. The registered enrollment target is 25 participants, below the 64-participant average among 7 other Hereditary Angioedema (HAE) trials with a reported enrollment target (61% lower). The trial reports 18 study locations across 18 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06846398, a Phase 2 study of Hereditary Angioedema (HAE), is active but no longer recruiting, sponsored by Shanghai Argo Biopharmaceutical Co..
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 18
- Study locations
Study Summary
A Phase 2 in Adult Subjects with Hereditary Angioedema
Primary Outcome
Change in time-normalized monthly (per 4 weeks) HAE attack rate from baseline to Day169
Conditions Studied
Interventions
- DRUG BW-20805
Study Locations (18)
Maryland
- Institute for Asthma and Allergy - Wheaton - Silver Spring
Missouri
- Washington University School of Medicine - St Louis
North Carolina
- Duke University Medicine Center - Durham
Pennsylvania
- Penn State Milton S. Hershey MC - Penn State - Hershey
Virginia
- Inova Clinical Trials and Research Center - Falls Church
Beijing Municipality
- Peking Union Medical College Hospital - Beijing
Gansu
- The First Hospital of Lanzhou University - Lanzhou
Hubei
- Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology - Wuhan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2025-02-28 |
| Est. Completion | 2028-03-30 |
| Phase | Phase 2 |
What the registry record for NCT06846398 still lists
NCT06846398 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 64-participant average among 7 other Hereditary Angioedema (HAE) trials with a reported enrollment target (61% lower).
The record links to 1 condition, with Hereditary Angioedema (HAE) appearing as the primary indexed condition, and to 1 intervention - of which BW-20805 is the first listed.
NCT06846398 lists 18 locations in 18 states (Maryland, Missouri, North Carolina).
Frequently Asked Questions
What is clinical trial NCT06846398 about?
NCT06846398 is a clinical study titled "A Phase 2 in Adult Subjects With Hereditary Angioedema". A Phase 2 in Adult Subjects with Hereditary Angioedema
What is the current status of trial NCT06846398?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2025-02-28. Estimated completion is 2028-03-30.
What conditions does trial NCT06846398 study?
This clinical trial studies the following conditions: Hereditary Angioedema (HAE).
What interventions are being tested in trial NCT06846398?
The interventions under investigation include: BW-20805 (DRUG).
Who is sponsoring clinical trial NCT06846398?
This trial is sponsored by Shanghai Argo Biopharmaceutical Co., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06846398 being conducted?
This trial has 18 study locations across Maryland, Missouri, North Carolina, Pennsylvania, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hereditary Angioedema (HAE)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CINRYZE for the Treatment of Hereditary Angioedema Attacks in Children Under the Age of 12
COMPLETED · Phase 2
-
Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients
RECRUITING · Phase 1
-
A Study of Navenibart in Participants With Hereditary Angioedema
RECRUITING · Phase 3
-
Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
RECRUITING · Phase 3
-
Donidalorsen Treatment in Children With Hereditary Angioedema
RECRUITING · Phase 3
-
Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI